Purpose of the Procedure
- Determine if the cancer is HER2-positive.
- Identify eligibility for targeted therapies like Trastuzumab.
- Predict prognosis and tumor aggressiveness.
Book HER2 Receptor Test in Saudi Arabia | Lahalak Medical Platform
A critical diagnostic test to determine if breast or gastric tumors respond to targeted therapies. This precision analysis helps oncologists design personalized treatment plans for significantly better clinical outcomes.
Scientific name: HER2/neu Expression Analysis (IHC/FISH)
A laboratory test performed on tissue biopsy samples to detect HER2 protein overexpression. Utilizing IHC or FISH techniques, it guides targeted therapy selection for breast and gastric cancer patients.
Service type
Laboratory test (Histopathology)
Duration
3-5 working days
Fasting
Fasting is not required
Included Services
- Tissue sample analysis
- Detailed medical report
- IHC or FISH technique determination
Medical Service Information
Target Groups
- Patients with newly diagnosed invasive breast cancer.
- Patients with advanced or metastatic gastric cancer.
- Recurrent cancer cases to re-evaluate receptor status.
Understanding Results
- Positive (3+): Indicates a high likelihood of responding to targeted therapy.
- Negative (0 or 1+): Indicates targeted therapy may not be effective.
- Equivocal (2+): Requires additional testing via FISH for confirmation.
Conditions & Notices
- Must provide properly preserved tissue biopsy sample
- Attach previous medical reports for the case
Medical services you might also like
